China drug licensing deals surge nearly 10-fold in value since 2021
Source: SeekingAlpha
2026-02-19 13:31:04 ET
More on AbbVie, AstraZeneca PLC, etc.
- Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game
- Pfizer: The Rebound Looks Unsustainable
- AbbVie: Dominating Immunology While Building Oncology Upside
- Merck posts new Enflonsia RSV data in infants
- Merck reports positive phase 3 second-season RSV data for ENFLONSIA
Read the full article on Seeking Alpha
For further details see:
China drug licensing deals surge nearly 10-fold in value since 2021
Astellas Pharma Inc
NASDAQ: ALPMF
ALPMF Trading
3.4% G/L:
$14.30 Last:
267 Volume:
$14.30 Open:
ALPMF Latest News
ALPMF Stock Data
$28,999,226,915
1,808,873,137
N/A
N/A
Pharmaceuticals
Healthcare
JP
Chuo-Ku
